Biosenta Inc. Logo

Biosenta Inc.

ZRO.CN

(1.8)
Stock Price

0,10 CAD

-2044.83% ROA

88.91% ROE

-0.36x PER

Market Cap.

2.867.750,00 CAD

-74.79% DER

0% Yield

-3353.66% NPM

Biosenta Inc. Stock Analysis

Biosenta Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Biosenta Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

2 PBV

The stock's low PBV ratio (-2.38x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-6%), which means it has a small amount of debt compared to the ownership it holds

4 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

5 ROE

The stock's ROE indicates a negative return (-69.09%) on shareholders' equity, suggesting poor financial performance.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Biosenta Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Biosenta Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Buy

Biosenta Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Biosenta Inc. Revenue
Year Revenue Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 339.780 100%
2014 58.367 -482.14%
2015 122.878 52.5%
2016 80.487 -52.67%
2017 17.178 -368.55%
2018 1.167 -1371.98%
2019 0 0%
2020 1.530 100%
2021 168.105 99.09%
2022 1.151 -14505.13%
2023 788 -46.07%
2023 1.042 24.38%
2024 801.008 99.87%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Biosenta Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 239.619 100%
2013 118.353 -102.46%
2014 397.582 70.23%
2015 250.677 -58.6%
2016 30.510 -721.62%
2017 19.240 -58.58%
2018 4.826 -298.67%
2019 43.745 88.97%
2020 33.392 -31%
2021 80.566 58.55%
2022 103.052 21.82%
2023 34.628 -197.6%
2023 66.685 48.07%
2024 56.840 -17.32%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Biosenta Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2008 157.051
2009 34.022 -361.62%
2010 0 0%
2011 938.842 100%
2012 1.953.274 51.93%
2013 2.185.928 10.64%
2014 2.781.813 21.42%
2015 1.702.417 -63.4%
2016 799.364 -112.97%
2017 299.102 -167.25%
2018 258.559 -15.68%
2019 388.892 33.51%
2020 644.650 39.67%
2021 1.987.781 67.57%
2022 1.095.735 -81.41%
2023 1.925.664 43.1%
2023 1.385.645 -38.97%
2024 1.712.888 19.1%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Biosenta Inc. EBITDA
Year EBITDA Growth
2008 -157.051
2009 355.407 144.19%
2010 447.145 20.52%
2011 -1.018.004 143.92%
2012 -2.319.911 56.12%
2013 -1.978.751 -17.24%
2014 -2.243.712 11.81%
2015 -2.074.102 -8.18%
2016 -814.027 -154.8%
2017 -205.890 -295.37%
2018 -263.636 21.9%
2019 -512.747 48.58%
2020 -728.593 29.63%
2021 -2.019.634 63.92%
2022 -1.196.784 -68.76%
2023 -1.918.224 37.61%
2023 -1.446.474 -32.61%
2024 -975.560 -48.27%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Biosenta Inc. Gross Profit
Year Gross Profit Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 242.818 100%
2014 -53.213 556.31%
2015 34.880 252.56%
2016 25.390 -37.38%
2017 8.237 -208.24%
2018 755 -990.99%
2019 0 0%
2020 55 100%
2021 99.107 99.94%
2022 728 -13513.6%
2023 456 -59.65%
2023 427 -6.79%
2024 797.724 99.95%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Biosenta Inc. Net Profit
Year Net Profit Growth
2008 -77.042
2009 -331.972 76.79%
2010 -504.791 34.24%
2011 -845.648 40.31%
2012 -2.324.004 63.61%
2013 -2.282.911 -1.8%
2014 -4.449.316 48.69%
2015 -3.528.160 -26.11%
2016 2.747.197 228.43%
2017 -1.034.369 365.59%
2018 -1.189.646 13.05%
2019 -545.546 -118.07%
2020 -799.561 31.77%
2021 -2.052.118 61.04%
2022 -1.485.348 -38.16%
2023 -1.977.836 24.9%
2023 -6.299.754 68.6%
2024 -2.189.184 -187.77%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Biosenta Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 -1 0%
2013 -1 0%
2014 -1 0%
2015 -1 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Biosenta Inc. Free Cashflow
Year Free Cashflow Growth
2008 -84.541
2009 -19.350 -336.9%
2010 99 19645.45%
2011 -915.639 100.01%
2012 -1.450.239 36.86%
2013 -1.364.762 -6.26%
2014 -1.885.392 27.61%
2015 -1.316.330 -43.23%
2016 -589.110 -123.44%
2017 -217.456 -170.91%
2018 -225.064 3.38%
2019 -326.731 31.12%
2020 -319.729 -2.19%
2021 -672.287 52.44%
2022 -504.433 -33.28%
2023 -164.093 -207.41%
2023 -566.347 71.03%
2024 -196.865 -187.68%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Biosenta Inc. Operating Cashflow
Year Operating Cashflow Growth
2008 -84.541
2009 -19.350 -336.9%
2010 99 19645.45%
2011 -765.639 100.01%
2012 -1.087.437 29.59%
2013 -1.290.330 15.72%
2014 -1.832.596 29.59%
2015 -1.218.471 -50.4%
2016 -589.110 -106.83%
2017 -217.456 -170.91%
2018 -225.064 3.38%
2019 -326.731 31.12%
2020 -319.729 -2.19%
2021 -672.287 52.44%
2022 -504.433 -33.28%
2023 -164.093 -207.41%
2023 -550.788 70.21%
2024 -196.865 -179.78%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Biosenta Inc. Capital Expenditure
Year Capital Expenditure Growth
2008 0
2009 0 0%
2010 0 0%
2011 150.000 100%
2012 362.802 58.66%
2013 74.432 -387.43%
2014 52.796 -40.98%
2015 97.859 46.05%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 15.559 100%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Biosenta Inc. Equity
Year Equity Growth
2008 792.411
2009 460.439 -72.1%
2010 -44.352 1138.15%
2011 1.238.139 103.58%
2012 2.187.100 43.39%
2013 1.536.543 -42.34%
2014 891.918 -72.27%
2015 -2.510.400 135.53%
2016 1.258.944 299.41%
2017 244.075 -415.8%
2018 -903.905 127%
2019 -1.433.988 36.97%
2020 -1.867.989 23.23%
2021 -2.593.823 27.98%
2022 -2.924.641 11.31%
2023 -3.829.089 23.62%
2023 -7.855.771 51.26%
2024 -7.167.111 -9.61%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Biosenta Inc. Assets
Year Assets Growth
2008 803.411
2009 478.098 -68.04%
2010 2.807 -16932.35%
2011 1.762.161 99.84%
2012 3.745.151 52.95%
2013 3.932.456 4.76%
2014 2.927.405 -34.33%
2015 2.476.688 -18.2%
2016 2.478.400 0.07%
2017 1.611.369 -53.81%
2018 17.942 -8880.99%
2019 19.549 8.22%
2020 108.834 82.04%
2021 263.663 58.72%
2022 256.079 -2.96%
2023 256.756 0.26%
2023 107.592 -138.64%
2024 329.622 67.36%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Biosenta Inc. Liabilities
Year Liabilities Growth
2008 11.000
2009 17.659 37.71%
2010 47.159 62.55%
2011 524.022 91%
2012 1.558.051 66.37%
2013 2.395.913 34.97%
2014 2.035.487 -17.71%
2015 4.987.088 59.18%
2016 1.219.456 -308.96%
2017 1.367.294 10.81%
2018 921.847 -48.32%
2019 1.453.537 36.58%
2020 1.976.823 26.47%
2021 2.857.486 30.82%
2022 3.180.720 10.16%
2023 4.085.845 22.15%
2023 7.963.363 48.69%
2024 7.496.733 -6.22%

Biosenta Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-0.23
Price to Earning Ratio
-0.36x
Price To Sales Ratio
14.27x
POCF Ratio
-2.88
PFCF Ratio
-3.31
Price to Book Ratio
-0.34
EV to Sales
40.91
EV Over EBITDA
-7.5
EV to Operating CashFlow
-9.67
EV to FreeCashFlow
-9.5
Earnings Yield
-2.76
FreeCashFlow Yield
-0.3
Market Cap
0,00 Bil.
Enterprise Value
0,01 Bil.
Graham Number
1.15
Graham NetNet
-0.25

Income Statement Metrics

Net Income per Share
-0.23
Income Quality
0.13
ROE
0.89
Return On Assets
-20.45
Return On Capital Employed
0.6
Net Income per EBT
1
EBT Per Ebit
6.09
Ebit per Revenue
-5.51
Effective Tax Rate
0.03

Margins

Sales, General, & Administrative to Revenue
5.82
Research & Developement to Revenue
0.39
Stock Based Compensation to Revenue
0.29
Gross Profit Margin
0.99
Operating Profit Margin
-5.51
Pretax Profit Margin
-33.54
Net Profit Margin
-33.54

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.03
Free CashFlow per Share
-0.03
Capex to Operating CashFlow
-0.02
Capex to Revenue
0.08
Capex to Depreciation
6.9
Return on Invested Capital
0.59
Return on Tangible Assets
-20.45
Days Sales Outstanding
470.36
Days Payables Outstanding
166949.45
Days of Inventory on Hand
5077.65
Receivables Turnover
0.78
Payables Turnover
0
Inventory Turnover
0.07
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,25
Tangible Book Value per Share
-0.25
Shareholders Equity per Share
-0.25
Interest Debt per Share
0.22
Debt to Equity
-0.75
Debt to Assets
16.26
Net Debt to EBITDA
-4.89
Current Ratio
0.15
Tangible Asset Value
-0,01 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
-1840153
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
38864
Debt to Market Cap
1.87

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Biosenta Inc. Dividends
Year Dividends Growth

Biosenta Inc. Profile

About Biosenta Inc.

Biosenta Inc. develops, manufactures, and sells anti-microbial chemical compounds for household and industrial applications in Canada. It is involved in developing true, an anti-microbial, dual-action disinfectant that kills viruses, bacteria, mold, and germs on contact. The company also intends to manufacture and distribute Tri-Filler, an anti-microbial filler to perform filling and bulking functions. Biosenta Inc. was founded in 1986 and is based in Toronto, Canada.

CEO
Mr. Amarvir Singh Gill
Employee
0
Address
18 Wynford Drive
Toronto, M3C 3S2

Biosenta Inc. Executives & BODs

Biosenta Inc. Executives & BODs
# Name Age
1 Mr. Amarvir Singh Gill
President, Chief Executive Officer, Interim Chief Financial Officer & Director
70

Biosenta Inc. Competitors